Cellectis AB, a subsidiary of Takara Holdings, Inc., is a Swedish company located in Gothenburg. The firm manufactures and distributes stem cell-related products. On September 04, 2014 Takara Bio, Inc. acquired Cellectis AB from Cellectis SA.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

RBio is superior pharmaceutical production standards (GMP) in the appropriate cell therapy manufacturing facilities were seolrim derived from adipose tissue for stem cell therapy in the world No.1 in technology of rare, incurable diseases and other treatment difficult disease for clinical trials and progress and We are devoting ourselves to commercializing therapeutics.

PROSTEMICS Co., Ltd. engages in the provision of stem cell cosmetics and medicine. It operates through cosmetic and stem cell medicine business divisions. The cosmetic business division provides cosmetics which contain stem cell culture medium. The stem cell medicine business division researches and develops stem cell cures. The company was founded on September 2, 2005 and is headquartered in Seoul, South Korea.

Guangzhou Saliai Stemcell Science & Technology Co., Ltd. engages in the provision of stem cell storage, health supplements, biological products, and related health management services. The firm involves in the production of regenerative medicine devices, medical nutrition supplements, and biological & medical cosmetic products. It operates a research and development platform which includes life bank, health management center, medical center, and medical cell center. The company was founded by Hai Jia Chen and Ming Jia Chen on July 7, 2009 and is headquartered in Guangzhou, China.

Anterogen Co., Ltd. engages in the development and sale of stem cell therapy treatments. Its products include Cupistem and Remodullin injection, Queencell, and stem cell conditioned media. It also offers stem cell banking and analysis services. The company was founded on March 16, 2000 and is headquartered in Seoul, South Korea.

Celularity, Inc. a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through the following segments: Cell Therapy, BioBanking, Degenerative Disease, and Other. The Cell Therapy segment consists of the therapies the company is researching and developing. The BioBanking segment focuses on stem cells from umbilical cords and placentas and provides storage of such cells on behalf of individuals for future use. The Degenerative Disease segment offers products used in surgical and wound care markets. The company was founded by Robert J. Hariri in 2016 and is headquartered in Florham Park, NJ.

Vivalis SA manufactures human and animal vaccines. The firm specializes in the research and development of vaccines and antiviral molecules, as well as in recombinant therapeutic protein and monoclonal antibody expression systems development. The firm's embryonic stem cells are used for practical applications in human and animal health. It also helps its clients in a case by case basis for the development of processes in the frame of service agreement. The company was founded in April 1999 and is headquartered in France.

Arizona Board of Regents oversees college activities. The company was founded in 1864 and is headquartered in Phoenix, AZ.

Anthrogenesis, based in Cedar Knolls, New Jersey, is a biotherapeutics company that has developed proprietary methods for collecting, processing and storing stem cells and other valuable biomaterials derived from human placental tissue. Anthrogenesis is focused on developing and delivering therapies using stem cells sourced from human placental tissue to treat cancers and immunological, metabolic and inflammatory diseases. Anthrogenesis has demonstrated that the human placenta is an abundant source of biotherapies, including early stage stem cells and other biomaterials for organ and tissue repair. Anthrogenesis also operates Lifebank, a state-licensed blood bank that banks stem cell transplant units derived from placental tissue and in some cases, blood from the umbilical cord that is collected immediately after birth.

Established in 1945, Amorepacific is Korea’s No.1 beauty company and a blue-chip corporation. Amorepacific owns nearly 30 well-known brands and has been developing rapidly worldwide. Amorepacific pays great attention to product research and development through research centers located in Korea, France, Japan and Shanghai, to develop premium and high quality skincare and cosmetics products. The Group chose Hong Kong as a strategic bridgehead for the expansion of its presence across the Greater China region and the rest of the world. Two flagship brands - LANEIGE and Sulwhasoo, were introduced in Hong Kong in 2002 and 2004 respectively. The eponymous luxury brand – AMOREPACIFIC, was introduced in Hong Kong in 2014. In 2015, ETUDE HOUSE, a playful cosmetics brand, made its debut in the territory. In 2018, the Company set foot in the personal care product market, introducing the Group’s legendary hair care brand ‘Ryo’ into Hong Kong.

MJN U.S. Holdings LLC, part of Reckitt Benckiser Group Plc, is a company headquartered in the United States that functions as an investment holding company.

Korea Research Institute of Bioscience and Biotechnology (KRIBB) is a government research institute in Daejeon, South Korea. It is dedicated to biotechnology research across a broad span of expertise, from basic studies for the fundamental understanding of life phenomena to applied studies such as drug discovery, novel biomaterials, integrated biotechnology and bioinformation.

Massachusetts General Hospital was established to provide care to Boston's sick, regardless of socioeconomic status—an innovative idea in 1811. In the words of their founder, John Warren, MD, “When in distress, every man becomes their neighbor.” They subsequently became the first teaching hospital for Harvard University’s new medical school and have been redefining excellence in healthcare ever since. They have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse community they were created to serve. They believe that because of diversity they excel, through inclusion they respect their community, and with a keen focus on equity they serve, heal, educate and innovate at the highest levels. Their first priority is the well-being of their patients—near and far. As a team they are able to maintain a singular focus on providing the highest quality, most compassionate care to each and every patient.

Otsuka Pharmaceutical Factory, Inc. manufactures and distributes pharmaceutical and nutritional products. Its products include medical foods, hine E-gel, processlead, engelead, innerpower, oronine h ointment, urepearl plus lotion 10 and urepearl plus cream. The company was founded on September 1, 1921 and is headquartered in Naruto, Japan.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

PrimeGen Biotech is located in Santa Ana, California and operates a 10,000 sq2. ft facility. The newly renovated facility consists of modern laboratories capable of cell processing, cell culture, molecular biology, flow cytometry, and histology. The laboratories are developed to specifically meet the requirements of our unique research approaches. The PrimeGen team includes research scientists and specialists with many years of experience in basic research of adult stem cells. As PrimeGen Biotech grows, it will remain dedicated to discovering the best possible applications for stem cell therapies and to translate the findings to therapeutic applications.

BioRestorative Therapies is a development stage company, develops medical procedures using cell and tissue protocols, primarily involving adult stem cells, designed for patients to undergo minimally invasive cellular-based treatments. The company focuses on the development of the ThermoStem Program that engages in the use of brown fat in connection with the cell-based treatment of Type 2 diabetes, obesity, hypertension, other metabolic disorders, and cardiac deficiencies, as well as is involved in the study of stem cells, several genes, proteins, and/or mechanisms, which are related to these diseases and disorders. It also focuses on the development of brtxDISC (Disc Implanted Stem Cells) Program for the adult stem cell treatment of disc and spine conditions, including bulging and herniated discs.

Cellular Biomedicine Group (Shanghai) Ltd. engages in development and sales of laboratory equipment and consumables, biological reagents. The company was founded on October 19, 2011 and is headquartered in Shanghai, China.